Google Chrome
Safari
Firefox
Edge
Knowledge Center
Article / Jul 27, 2015
Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma
Source:
Manufacturing Chemist, 27 July 2015
Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.
Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.
Related links
Also in the Knowledge Center
Scientific Article
/ Apr 16, 2020
Macrocyclic lactone formulations, methods of their preparation and use of the formulations in treating pathologies secondary to ophthalmic parasites
Read more
Scientific Article
/ Jan 05, 2020
A multicentre, randomized, double‐masked, parallel group, vehicle‐controlled phase IIb study
Read more
Scientific Article